4,5-dihydro-2H-benzo[e]indazole | 2969-56-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4,5-dihydro-2H-benzo[e]indazole
• 英文别名: 4,5-dihydro-2(3)H-benzo[e]indazole；4,5-dihydro-3H-benzo[e]indazole
• CAS: 2969-56-4
• 化学式: C₁₁H₁₀N₂
• 分子量: 170.214
• InChiKey: PMZFMFVUBLVADX-UHFFFAOYSA-N

物化性质

• 沸点：
  387.1±11.0 °C(Predicted)
• 密度：
  1.236±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-茚酮 在 水 、 caesium carbonate 作用下， 以 甲醇 、 二甲基亚砜 为溶剂， 反应 8.0h， 生成 4,5-dihydro-2H-benzo[e]indazole
  参考文献：
  名称：

  由环酮一锅法合成螺环或稠合吡唑：碳化钙作为扩环中的碳源

  摘要：

  由环状酮原位生成的N-甲苯磺酰azo平稳地进行[3 + 2]环加成反应，得到饱和的螺环吡唑，并在某些情况下通过扩环进一步转化为稠合类似物。一种廉价且可再生的资源电石用作扩环中的碳源。该反应的显着特征包括广泛可用的起始原料，方便的一锅/两步法，高效率和高区域选择性。值得注意的是，该反应经历了[1,5]-σ重排过程，氘标记实验对此进行了支持。

  DOI：

  10.1021/acs.joc.7b01496

文献信息

• [EN] PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] DÉRIVÉS D'ACIDE CARBONIQUE SUBSTITUÉS PAR PYRAZOLYLE EN TANT QUE MODULATEURS DU RÉCEPTEUR DE LA PROSTACYCLINE PGI2 ADAPTÉS AU TRAITEMENT DE TROUBLES LE FAISANT INTERVENIR
  申请人：ARENA PHARM INC

  公开号：WO2010068242A1

  公开（公告）日：2010-06-17

  Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

  Formula Ia的吡唑衍生物及其药物组成物，可调节PGI2受体的活性。本发明的化合物和药物组成物用于治疗以下疾病：肺动脉高压（PAH）及相关疾病；血小板聚集；冠状动脉疾病；心肌梗死；短暂性缺血性发作；心绞痛；中风；缺血再灌注损伤；再狭窄；心房颤动；血栓形成在冠状动脉成形术或冠状动脉旁路手术个体中或在患有心房颤动的个体中；动脉粥样硬化；动脉粥样血栓形成；哮喘或其症状；糖尿病相关疾病，如糖尿病周围神经病变、糖尿病肾病或糖尿病视网膜病变；青光眼或其他眼睛异常眼压疾病；高血压；炎症；牛皮癣；银屑病性关节炎；类风湿性关节炎；克罗恩病；移植排斥；多发性硬化症；系统性红斑狼疮（SLE）；溃疡性结肠炎；缺血再灌注损伤；再狭窄；动脉粥样硬化；痤疮；1型糖尿病；2型糖尿病；败血症；慢性阻塞性肺疾病（COPD）。
• Convenient one-pot syntheses of pyrazoles from imines, a vilsmeier type reagent and hydrazine
  作者：Alan R. Katritzky、Anna Denisenko、Sergey N. Denisenko、Michael Arend

  DOI：10.1002/jhet.5570370548

  日期：2000.9

  one-pot procedure for the regioselective synthesis of pyrazoles from readily available starting materials is described. Vilsmeier type reagent 1 reacts with imines 10 (via the corresponding tautomeric secondary enamines) in tetrahydrofuran to give enaminoimine hydrochlorides 11. Nonsymmetrical imines generally react preferentially with 1 at the sterically less hindered α-position. The enaminoimine hydrochlorides

  描述了一种简单的一锅法，用于从容易获得的起始原料进行区域选择性合成吡唑。Vilsmeier型试剂1与亚胺10（通过相应的互变异构仲烯胺）在四氢呋喃中反应，得到烯氨基亚胺盐酸盐11。非对称亚胺通常在空间受阻较小的α位置优先与1反应。通过加入肼，将烯氨基亚胺盐酸盐11以中等至高产率原位转化为相应的吡唑12。
• Substituted 4,5-Dihydro-2H-Benzo[e]Indazole-9-Carboxylates For The Treatment Of Diabetes And Related Disorders
  申请人：Council of Scientific & Industrial Research

  公开号：US20150005357A1

  公开（公告）日：2015-01-01

  The present invention relates to the development of novel substituted 4,5-dihydro-2H-benzo[e]indazole-9-carboxylates, which can be used as therapeutic agents for the treatment and prevention of metabolic disorders, and a process of preparing said novel compounds. More particularly, the present invention relates to substituted 4,5-dihydro-2H-benzo[e]indazole-9-carboxylates and their related compounds, processes for preparing the said compounds and to their use in the treatment of diabetes and related metabolic disorders.

  本发明涉及新型取代的4,5-二氢-2H-苯并[e]吲唑-9-羧酸酯的研发，该化合物可用作治疗和预防代谢性疾病的治疗剂，以及制备该新型化合物的方法。更具体地，本发明涉及取代的4,5-二氢-2H-苯并[e]吲唑-9-羧酸酯及其相关化合物，制备该化合物的方法以及它们在治疗糖尿病和相关代谢性疾病方面的应用。
• PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：Tran Thuy-Anh

  公开号：US20110224262A1

  公开（公告）日：2011-09-15

  Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

  公式Ia的吡唑衍生物及其制药组合物，用于调节PGI2受体的活性。本发明的化合物和制药组合物用于治疗以下疾病的有用方法：肺动脉高压（PAH）及相关疾病；血小板聚集；冠状动脉疾病；心肌梗死；短暂性脑缺血发作；心绞痛；中风；缺血再灌注损伤；再狭窄；房颤的血栓形成或在患有房颤的个体中的冠状动脉成形术或冠状动脉旁路手术；动脉粥样硬化；动脉粥样血栓形成；哮喘或其症状；与糖尿病相关的疾病，如糖尿病周围神经病、糖尿病肾病或糖尿病视网膜病变；青光眼或其他眼部异常眼压的疾病；高血压；炎症；牛皮癣；银屑病性关节炎；类风湿性关节炎；克罗恩病；移植排斥；多发性硬化症；系统性红斑狼疮（SLE）；溃疡性结肠炎；再灌注损伤；再狭窄；动脉粥样硬化；痤疮；1型糖尿病；2型糖尿病；败血症；慢性阻塞性肺疾病（COPD）。
• Pyrrol derivatives, uses thereof
  申请人：PTC Therapeutics, Inc.

  公开号：EP2316452A1

  公开（公告）日：2011-05-04

  The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.

  本发明涉及通过施用本发明的化合物或组合物治疗或预防与 mRNA 中无义突变相关的疾病的方法、化合物和组合物。更具体地说，本发明涉及抑制与 mRNA 中无义突变相关的过早翻译终止的方法、化合物和组合物。